Adaptive clinical trials are one of today’s best tools for finding new drugs that improve on existing therapies in targeted populations. Still, avoiding rejections means sponsors and CROs must know in advance what the FDA does — and doesn’t — want to see in everything from design through final data analysis.

That’s a little easier now that the FDA has begun to identify the adaptive trial models that it finds to be valid.

Now, take your own planning and preparation to the next level by turning the FDA’s preferences into rock-solid best practices for speeding your approval.

Before you begin to modify an existing trial, this report from FDAnews maps out the specific planning and preparation it takes to win FDA approval for adaptive clinical trials. By combining a concise overview with a detailed analysis of FDA’s preferences, this one report advises you on everything thing from the best trial model to use to the best way to avoid technical problems with final data analysis.

Buy now to turn the FDA’s own guidance and examples of acceptable modifications into real-world best practices for “rejection-proofing” your adaptive clinical trials, including:

Prospective Planning: How to anticipate the types of modification that will occur in trial design to avoid what the FDA does not want to see in terms of making changes to dosing, exclusion criteria, target subject populations and other criteria.

Controls: How to factor in bias and error controls early in the design phase to present the FDA with assurance that sponsors won’t simply see what they want to see in the interim results.

Protocols and Statistical Analysis Plans: How to pull all elements of the adaptive clinical trial together into protocols and plans that support the trial effectively from startup through reviews and final data analysis.

Trouble Shooting: How to spot and avoid common difficulties that may arise in adaptive trials; the FDA’s central concerns — the agency’s most frequent complaints about adaptive trials.

Don’t let technical problems derail your adaptive clinical trial! Rely on this management report for the best practices to help you enjoy maximum agility in winning approval and bringing new drugs to targeted populations.

ROs must know in advance what the FDA does — and doesn’t — want to see in everything from design through final data analysis.

That’s a little easier now that the FDA has begun to identify the adaptive trial models that it finds to be valid.

Now, take your own planning and preparation to the next level by turning the FDA’s preferences into rock-solid best practices for speeding your approval.

Before you begin to modify an existing trial, this report from FDAnews maps out the specific planning and preparation it takes to win FDA approval for adaptive clinical trials. By combining a concise overview with a detailed analysis of FDA’s preferences, this one report advises you on everything thing from the best trial model to use to the best way to avoid technical problems with final data analysis.

Buy now to turn the FDA’s own guidance and examples of acceptable modifications into real-world best practices for “rejection-proofing” your adaptive clinical trials, including:

Prospective Planning: How to anticipate the types of modification that will occur in trial design to avoid what the FDA does not want to see in terms of making changes to dosing, exclusion criteria, target subject populations and other criteria.

Controls: How to factor in bias and error controls early in the design phase to present the FDA with assurance that sponsors won’t simply see what they want to see in the interim results.

Protocols and Statistical Analysis Plans: How to pull all elements of the adaptive clinical trial together into protocols and plans that support the trial effectively from startup through reviews and final data analysis.

Trouble Shooting: How to spot and avoid common difficulties that may arise in adaptive trials; the FDA’s central concerns — the agency’s most frequent complaints about adaptive trials.

Don’t let technical problems derail your adaptive clinical trial! Rely on this management report for the best practices to help you enjoy maximum agility in winning approval and bringing new drugs to targeted populations.

Order Your Copy Today!

PDF Edition

Print Edition

Available Formats

PDF Edition – $377

Print Edition – $377

(Add $10 shipping and handling per book for printed books shipped to the US and Canada, or $35 per book for books shipped elsewhere. VA residents, please add 6 percent sales tax.)

Table of Contents

Multi-user Access

Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library – a personalized collection of FDAnews publications that is fully searchable. Contact Liz Lentz for a quote or more information.

Our Guarantee

Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price. Return the hard copy within 30 days (in resalable condition) to receive your refund (less shipping/handling).

Get Multi-user Access With The Electronic Books Library.
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the Electronic Books Library – a personalized collection of FDAnews publications that is fully searchable. Contact customer service for a quote or more information.

Need Extra Print Copies?Significant volume discounts are available for ordering three or more copies of the same book. You must order them at the same time and provide a single payment to take advantage of the discount. Simply choose the quantity you wish to order the discount will be calculated automatically.